APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin 12 Receptor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Interleukin 12 Receptor Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchInterleukin 12 Receptor Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin 12 Receptor Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Interleukin 12 Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin 12 Receptor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin 12 Receptor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Interleukin 12 Receptor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Interleukin 12 Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin 12 Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin 12 Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Interleukin 12 Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Interleukin 12 Receptor market include Merck KGaA, Eli Lilly and Company, Neumedicines Inc and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Interleukin 12 Receptor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin 12 Receptor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin 12 Receptor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Interleukin 12 Receptor market.

Interleukin 12 Receptor Segment by Company

Merck KGaA

Eli Lilly and Company

Neumedicines Inc

Mallinckrodt Plc

Interleukin 12 Receptor Segment by Type

LY-3232094

M-9241

NMIL-121

Edodekin Alfa SR

Others

Interleukin 12 Receptor Segment by Application

In-Patient

Out-Patient

Interleukin 12 Receptor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Interleukin 12 Receptor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Interleukin 12 Receptor key companies, revenue, market share, and recent developments.

3. To split the Interleukin 12 Receptor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Interleukin 12 Receptor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Interleukin 12 Receptor significant trends, drivers, influence factors in global and regions.

6. To analyze Interleukin 12 Receptor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 12 Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin 12 Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 12 Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Interleukin 12 Receptor industry.

Chapter 3: Detailed analysis of Interleukin 12 Receptor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Interleukin 12 Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Interleukin 12 Receptor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Interleukin 12 Receptor Industry Trends Table 2. Interleukin 12 Receptor Industry Drivers Table 3. Interleukin 12 Receptor Industry Opportunities and Challenges Table 4. Interleukin 12 Receptor Industry Restraints Table 5. Global Interleukin 12 Receptor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Interleukin 12 Receptor Revenue Share by Company (2021-2026) Table 7. Global Interleukin 12 Receptor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Interleukin 12 Receptor Key Company Manufacturing Base & Headquarters Table 9. Global Interleukin 12 Receptor Company, Product Type & Application Table 10. Global Interleukin 12 Receptor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Interleukin 12 Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of LY-3232094 Table 15. Significant Companies of M-9241 Table 16. Significant Companies of NMIL-121 Table 17. Significant Companies of Edodekin Alfa SR Table 18. Significant Companies of Others Table 19. Global Interleukin 12 Receptor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Interleukin 12 Receptor Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Interleukin 12 Receptor Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Interleukin 12 Receptor Sales Value Share by Type (2021-2026) Table 23. Global Interleukin 12 Receptor Sales Value Share by Type (2027-2032) Table 24. Significant Companies of In-Patient Table 25. Significant Companies of Out-Patient Table 26. Global Interleukin 12 Receptor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Interleukin 12 Receptor Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Interleukin 12 Receptor Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Interleukin 12 Receptor Sales Value Share by Application (2021-2026) Table 30. Global Interleukin 12 Receptor Sales Value Share by Application (2027-2032) Table 31. Global Interleukin 12 Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Interleukin 12 Receptor Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Interleukin 12 Receptor Sales Value Share by Region (2021-2026) Table 34. Global Interleukin 12 Receptor Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Interleukin 12 Receptor Sales Value Share by Region (2027-2032) Table 36. Global Interleukin 12 Receptor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Interleukin 12 Receptor Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Interleukin 12 Receptor Sales Value Market Share by Country (2021-2026) Table 39. Global Interleukin 12 Receptor Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Interleukin 12 Receptor Sales Value Market Share by Country (2027-2032) Table 41. Merck KGaA Company Information Table 42. Merck KGaA Business Overview Table 43. Merck KGaA Interleukin 12 Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Merck KGaA Interleukin 12 Receptor Product Portfolio Table 45. Merck KGaA Recent Development Table 46. Eli Lilly and Company Company Information Table 47. Eli Lilly and Company Business Overview Table 48. Eli Lilly and Company Interleukin 12 Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eli Lilly and Company Interleukin 12 Receptor Product Portfolio Table 50. Eli Lilly and Company Recent Development Table 51. Neumedicines Inc Company Information Table 52. Neumedicines Inc Business Overview Table 53. Neumedicines Inc Interleukin 12 Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Neumedicines Inc Interleukin 12 Receptor Product Portfolio Table 55. Neumedicines Inc Recent Development Table 56. Mallinckrodt Plc Company Information Table 57. Mallinckrodt Plc Business Overview Table 58. Mallinckrodt Plc Interleukin 12 Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Mallinckrodt Plc Interleukin 12 Receptor Product Portfolio Table 60. Mallinckrodt Plc Recent Development Table 61. Research Programs/Design for This Report Table 62. Authors List of This Report Table 63. Secondary Sources Table 64. Primary Sources List of Figures Figure 1. Interleukin 12 Receptor Product Image Figure 2. Global Interleukin 12 Receptor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin 12 Receptor Market Size (2021-2032) & (US$ Million) Figure 4. Global Interleukin 12 Receptor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. LY-3232094 Image Figure 8. M-9241 Image Figure 9. NMIL-121 Image Figure 10. Edodekin Alfa SR Image Figure 11. Others Image Figure 12. Global Interleukin 12 Receptor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Interleukin 12 Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Interleukin 12 Receptor Sales Value Share by Type (2021-2032) Figure 15. In-Patient Image Figure 16. Out-Patient Image Figure 17. Global Interleukin 12 Receptor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Interleukin 12 Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Interleukin 12 Receptor Sales Value Share by Application (2021-2032) Figure 20. Global Interleukin 12 Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Interleukin 12 Receptor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Interleukin 12 Receptor Sales Value (2021-2032) & (US$ Million) Figure 23. North America Interleukin 12 Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Interleukin 12 Receptor Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Interleukin 12 Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Interleukin 12 Receptor Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Interleukin 12 Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Interleukin 12 Receptor Sales Value (2021-2032) & (US$ Million) Figure 29. South America Interleukin 12 Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Interleukin 12 Receptor Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Interleukin 12 Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Interleukin 12 Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • LY-3232094
  • M-9241
  • NMIL-121
  • Edodekin Alfa SR
  • Others
Applications
  • In-Patient
  • Out-Patient
Companies covered
  • Merck KGaA
  • Eli Lilly and Company
  • Neumedicines Inc
  • Mallinckrodt Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Interleukin 12 Receptor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Interleukin 12 Receptor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Interleukin 12 Receptor Market Dynamics
  1. 2.1 Interleukin 12 Receptor Industry Trends
  2. 2.2 Interleukin 12 Receptor Industry Drivers
  3. 2.3 Interleukin 12 Receptor Industry Opportunities and Challenges
  4. 2.4 Interleukin 12 Receptor Industry Restraints
3 Interleukin 12 Receptor Market by Company
  1. 3.1 Global Interleukin 12 Receptor Company Revenue Ranking in 2025
  2. 3.2 Global Interleukin 12 Receptor Revenue by Company (2021-2026)
  3. 3.3 Global Interleukin 12 Receptor Company Ranking (2024-2026)
  4. 3.4 Global Interleukin 12 Receptor Company Manufacturing Base and Headquarters
  5. 3.5 Global Interleukin 12 Receptor Company Product Type and Application
  6. 3.6 Global Interleukin 12 Receptor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Interleukin 12 Receptor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Interleukin 12 Receptor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Interleukin 12 Receptor Market by Type
  1. 4.1 Interleukin 12 Receptor Type Introduction
  2. 4.1.1 LY-3232094
  3. 4.1.2 M-9241
  4. 4.1.3 NMIL-121
  5. 4.1.4 Edodekin Alfa SR
  6. 4.1.5 Others
  7. 4.2 Global Interleukin 12 Receptor Sales Value by Type
  8. 4.2.1 Global Interleukin 12 Receptor Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Interleukin 12 Receptor Sales Value by Type (2021-2032)
  10. 4.2.3 Global Interleukin 12 Receptor Sales Value Share by Type (2021-2032)
5 Interleukin 12 Receptor Market by Application
  1. 5.1 Interleukin 12 Receptor Application Introduction
  2. 5.1.1 In-Patient
  3. 5.1.2 Out-Patient
  4. 5.2 Global Interleukin 12 Receptor Sales Value by Application
  5. 5.2.1 Global Interleukin 12 Receptor Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Interleukin 12 Receptor Sales Value by Application (2021-2032)
  7. 5.2.3 Global Interleukin 12 Receptor Sales Value Share by Application (2021-2032)
6 Interleukin 12 Receptor Regional Value Analysis
  1. 6.1 Global Interleukin 12 Receptor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin 12 Receptor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Interleukin 12 Receptor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Interleukin 12 Receptor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Interleukin 12 Receptor Sales Value (2021-2032)
  7. 6.3.2 North America Interleukin 12 Receptor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Interleukin 12 Receptor Sales Value (2021-2032)
  10. 6.4.2 Europe Interleukin 12 Receptor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Interleukin 12 Receptor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Interleukin 12 Receptor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Interleukin 12 Receptor Sales Value (2021-2032)
  16. 6.6.2 South America Interleukin 12 Receptor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Interleukin 12 Receptor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Interleukin 12 Receptor Sales Value Share by Country, 2025 VS 2032
7 Interleukin 12 Receptor Country-level Value Analysis
  1. 7.1 Global Interleukin 12 Receptor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Interleukin 12 Receptor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Interleukin 12 Receptor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Interleukin 12 Receptor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Interleukin 12 Receptor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Interleukin 12 Receptor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Interleukin 12 Receptor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck KGaA
  2. 8.1.1 Merck KGaA Company Information
  3. 8.1.2 Merck KGaA Business Overview
  4. 8.1.3 Merck KGaA Interleukin 12 Receptor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck KGaA Interleukin 12 Receptor Product Portfolio
  6. 8.1.5 Merck KGaA Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Interleukin 12 Receptor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Interleukin 12 Receptor Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Neumedicines Inc
  14. 8.3.1 Neumedicines Inc Company Information
  15. 8.3.2 Neumedicines Inc Business Overview
  16. 8.3.3 Neumedicines Inc Interleukin 12 Receptor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Neumedicines Inc Interleukin 12 Receptor Product Portfolio
  18. 8.3.5 Neumedicines Inc Recent Developments
  19. 8.4 Mallinckrodt Plc
  20. 8.4.1 Mallinckrodt Plc Company Information
  21. 8.4.2 Mallinckrodt Plc Business Overview
  22. 8.4.3 Mallinckrodt Plc Interleukin 12 Receptor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mallinckrodt Plc Interleukin 12 Receptor Product Portfolio
  24. 8.4.5 Mallinckrodt Plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst